Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. BRD4 BD1 compound 12m: sourced facts only. name: "Among them, the representative compound 12m showed potent BRD4 BD1 inhibitory activity, of which the inhibition rate is better than the other compounds." [PMID:39823809]; target: "Among them, the representative compound 12m showed potent BRD4 BD1 inhibitory activity, of which the inhibition rate is better than the other compounds." [PMID:39823809]; developer: "Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, PR China." [PMID:39823809]; stage: "In MV4-11 cell line, compound 12m also showed excellent anti-cancer activity (IC50 = 0.02 μM), which is superior to (+)-JQ1 (IC50 = 0.03 μM)." [PMID:39823809]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on China Pharma Univ. BRD4 BD1 compound 12m.